- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04068896
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
May 2, 2023 updated by: NGM Biopharmaceuticals, Inc
A Phase 1/2 Dose-Finding Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy
Study of NGM120 in subjects with advanced solid tumors and and pancreatic cancer (Part 1 and 2) and metastatic castration resistant prostate cancer (Part 3).
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
75
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: NGM Study Director
- Phone Number: 650-243-5555
- Email: ngm120@ngmbio.com
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85719
- NGM Clinical Study Site
-
-
California
-
Los Angeles, California, United States, 90048
- NGM Clinical Study Site
-
Los Angeles, California, United States, 90084
- NGM Clinical Study Site
-
Sacramento, California, United States, 98517
- NGM Clinical Study Site
-
San Diego, California, United States, 92123
- NGM Clinical Study Site
-
Santa Monica, California, United States, 90404
- NGM Clinical Study Site
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- NGM Clinical Study Site
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- NGM Clinical Study Site
-
-
Florida
-
Miami, Florida, United States, 33136
- NGM Clinical Study Site
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- NGM Clinical Study Site
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- NGM Clinical Study Site
-
-
Nebraska
-
Omaha, Nebraska, United States, 68130
- NGM Clinical Study Site
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28204
- NGM Clinical Study Site
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- NGM Clinical Study Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19111
- NGM Clinical Study Site
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- NGM Clinical Study Site
-
Myrtle Beach, South Carolina, United States, 29572
- NGM Clinical Study Site
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- NGM Clinical Study Site
-
-
Texas
-
Dallas, Texas, United States, 75390
- NGM Clinical Study Site
-
Houston, Texas, United States, 77030
- NGM Clinical Study Site
-
-
Washington
-
Seattle, Washington, United States, 98101
- NGM Clinical Study Site
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- NGM Clinical Study Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria (Part 1 and 2):
- Have histologically confirmed metastatic pancreatic adenocarcinoma. Recurrent unresectable pancreatic cancer is acceptable as long as the treatment is first-line.
- Have not received any approved chemotherapy, except in the adjuvant setting.
- Life expectancy of at least 12 weeks
- Male subjects must agree to use contraception as per protocol during the treatment period and for at least 90 days after the last study treatment administration and refrain from donating sperm during this period.
- Provision of an archival tumor sample (within 5 years). If an archival sample is unavailable, a fresh biopsy can be obtained during Screening. If archival tissue or biopsy sample is unavailable, the subject is ineligible.
Inclusion Criteria (Part 3 Prostate Cancer):
- Metastatic, castrate resistance, histologically confirmed prostate cancer; continuous medical castration for ≥8 weeks prior to screening.
- Effective castration with serum testosterone levels <0.5 ng/mL (50 ng/dL; 1.7 nmol/L).
- Have serum GDF15 levels ≥1300 pg/mL.
- Have experienced PSA progression under 1 or more lines of ADT in the absence or presence of radiographic and/or clinical progression, who decline or are not eligible to receive chemotherapy.
- Have had PSA doubling time of >3 months.
Exclusion Criteria (All parts):
- Subject was using immunosuppressive medications within 14 days before Screening with the exception of topical (intranasal, inhaled, and local injection), systemic (prednisone equivalent 10 mg/day or less), or as needed for hypersensitivity reactions such as computed tomography (CT) scan premedication.
- Subject has active infections or other serious underlying significant medical illness, abnormal and clinically significant laboratory findings or psychiatric illness/social situation.
- Subject is using a pacemaker, implantable cardiac defibrillator, neurostimulator, cochlear implants, cochlear implants, or other electronic medical equipment.
- Subject has documented immunodeficiency or organ transplant.
- Subject has an untreated central nervous system disease, leptomeningeal disease or cord compression.
- Subject has a history, or presence, of significant cardiovascular diseases; including uncontrolled hypertension, clinically relevant cardiac arrhythmia, unstable angina or myocardial infarction within 6 months before randomization, congestive heart failure > New York Heart Association Class II, severe peripheral vascular disease, corrected QT (QTc) prolongation >470 msec, clinically significant pericardial effusion.
- Subject has a history or presence of documented inflammatory bowel disease.
- Subject is known to be positive for human immunodeficiency virus (HIV) infection.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Placebo
|
Experimental: NGM120 Dose 1
NGM120 Subcutaneous Injection
|
NGM120 Dose 1
NGM120 Dose 2
NGM120 Dose 3
NGM120 Dose 4
NGM120 Dose 5
NGM120 Dose 6
|
Experimental: NGM120 Dose 2
NGM120 Subcutaneous Injection
|
NGM120 Dose 1
NGM120 Dose 2
NGM120 Dose 3
NGM120 Dose 4
NGM120 Dose 5
NGM120 Dose 6
|
Experimental: NGM120 Dose 3
NGM120 Subcutaneous Injection
|
NGM120 Dose 1
NGM120 Dose 2
NGM120 Dose 3
NGM120 Dose 4
NGM120 Dose 5
NGM120 Dose 6
|
Experimental: NGM120 Dose 4
NGM120 Subcutaneous Injection
|
NGM120 Dose 1
NGM120 Dose 2
NGM120 Dose 3
NGM120 Dose 4
NGM120 Dose 5
NGM120 Dose 6
|
Experimental: NGM120 Dose 5
NGM120 Subcutaneous Injection
|
NGM120 Dose 1
NGM120 Dose 2
NGM120 Dose 3
NGM120 Dose 4
NGM120 Dose 5
NGM120 Dose 6
|
Experimental: NGM120 Dose 6
NGM120 Subcutaneous Injection
|
NGM120 Dose 1
NGM120 Dose 2
NGM120 Dose 3
NGM120 Dose 4
NGM120 Dose 5
NGM120 Dose 6
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients with Dose-Limiting Toxicities:
Time Frame: 12 weeks
|
A DLT is defined as an AE that meets at least one of the criteria listed in protocol, according to National Cancer Institute (NCI) common terminology criteria for AE (CTCAE) version 5.0 and is considered by the investigator to be clinically relevant and attributed to the study treatment during the first 28 days after the first dose of study treatment.
|
12 weeks
|
Incidence of Adverse Events
Time Frame: 12 weeks
|
Number of patients with adverse events (AEs) according to severity, seriousness, and relationship to study drug
|
12 weeks
|
Number of Patients with Clinically Significant Laboratory Abnormalities:
Time Frame: 12 weeks
|
Number of patients with clinically significant change from baseline in laboratory abnormalities as characterized by type, frequency, severity (graded by CTCAE version 5.0) and timing.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics (PK) of NGM120
Time Frame: 19 weeks
|
Pharmacokinetics (PK) of NGM120 by measuring serum concentration of NGM120 at specified timepoints
|
19 weeks
|
Immunogenicity against NGM120
Time Frame: 19 weeks
|
Immunogenicity against NGM120 by measuring percentage of subjects to develop antidrug antibodies and neutralizing antibodies
|
19 weeks
|
Assessment of Antitumor and Anticachexia Activity Assessed using the RECIST Version 1.1 criteria
Time Frame: 19 weeks
|
Assessment of Antitumor and Anticachexia Activity Assessed using the RECIST Version 1.1 criteria
|
19 weeks
|
Body weight during therapy with NGM120
Time Frame: 19 weeks
|
Body weight during therapy with NGM120 by measuring change in body weight (in lb).
|
19 weeks
|
Skeletal muscle index during therapy with NGM120
Time Frame: 19 weeks
|
Skeletal muscle index during therapy with NGM120 by measuring skeletal muscle mass and adiposity at level of L3 on serial CT scan.
|
19 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 16, 2019
Primary Completion (Anticipated)
July 1, 2024
Study Completion (Anticipated)
January 1, 2025
Study Registration Dates
First Submitted
August 22, 2019
First Submitted That Met QC Criteria
August 23, 2019
First Posted (Actual)
August 28, 2019
Study Record Updates
Last Update Posted (Estimate)
May 4, 2023
Last Update Submitted That Met QC Criteria
May 2, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18-0402
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Melanoma
-
H. Lee Moffitt Cancer Center and Research InstituteTurnstone Biologics, Corp.RecruitingMetastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous MelanomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IA Melanoma | Stage IB Melanoma | Stage IIA MelanomaUnited States
-
MelanomaPRO, RussiaRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma, Stage II | Melanoma, Uveal | Melanoma in Situ | Melanoma, OcularRussian Federation
-
National Cancer Institute (NCI)CompletedStage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIB Melanoma | Stage IIC MelanomaUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); University of VirginiaCompletedStage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma | Stage 0 Skin Melanoma | Stage I Skin Melanoma | Stage II Skin MelanomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Melanoma | Stage IV Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage...United States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA MelanomaUnited States
-
BiocadRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma Metastatic | Melanoma Unresectable | Melanoma AdvancedIndia, Russian Federation, Belarus
-
Emory UniversityGenentech, Inc.Active, not recruitingStage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Unresectable Melanoma | Stage III Melanoma | Stage IIIA Skin Melanoma | Cutaneous Melanoma, Stage III | Cutaneous Melanoma, Stage IVUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States